See today's pick now. ViiV Healthcare announced Wednesday the latest findings from its EMBRACE phase 2b study. The study found that N6LS (VH3810109 or VH109), given every four months in ...

(RTTNews) - GSK plc (GSK)'s subsidiary ViiV Healthcare, Thursday announced the completion of negotiations with the pan-Canadian Pharmaceutical Alliance or pCPA for APRETUDE for pre-exposure ...